Bausch & Lomb licenses glaucoma candidate from NicOx for up to $180 million
This article was originally published in Scrip
Executive Summary
NicOx has signed a licensing agreement which grants Bausch & Lomb exclusive worldwide rights to develop and commercialise NCX 116, a nitric oxide-donating prostaglandin F2α-analogue, which has completed two Phase II studies in patients with glaucoma and ocular hypertension.